SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

On July 17, 2026, SystImmune Inc. revealed that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., obtained regulatory clearance from China's National Medical Products Administration (NMPA) for izalontamab (iza-bren).